Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
Nadeem Ali Dhirani,1 Yelin Yang,2 Sohel Somani2–4 1Wayne State University School of Medicine, Detroit, MI, USA; 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, 3William Osler Health System, Brampton, ON, 4Uptown Eye Specialists, Brampton, ON, Canada...
Guardado en:
Autores principales: | Dhirani NA, Yang Y, Somani S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe50737c5636461a91493d5b859f8bd9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pluronic® P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
por: Pellosi DS, et al.
Publicado: (2016) -
Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy
por: Shimizu K, et al.
Publicado: (2017) -
Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018) -
Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy
por: Asahi MG, et al.
Publicado: (2017) -
Central Serous Chorioretinopathy: Pathogenesis and Management
por: Semeraro F, et al.
Publicado: (2019)